The Trump administration is “very eager” to create a pathway for access to psychedelic therapy, Robert F. Kennedy Jr. According to the secretary of the US Department of Health and Human Services (HHS), and senior officials of federal agencies want to “communicate to the public as soon as possible.”
In an interview on the Joe Rogan Experience podcast released Friday, Kennedy said he’s confident “we’re going to get it,” with plans to develop and finalize rules that would allow patients with conditions like post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled environment.”
The secretary has been noted for his advocacy of psychedelic reform, an idea he floated as a 2024 Democratic presidential candidate before ultimately becoming the nation’s top health official under the Trump administration.
The president himself has been silent on the issue, but as Kennedy points out, support for expanding access to research and new therapeutics extends beyond HHS, with the heads of the US Department of Veterans Affairs (VA), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) also looking to take advantage of the potential benefits of psychedelic drugs.
“Everybody in my agency, and in (Secretary Doug Collins’) agency at the VA, is very eager to get a rule that will allow these types of studies and allow them to go into therapeutic settings, particularly for military personnel who have suffered these injuries to have access to these products,” Kennedy said. “We are working on that process now. We are all working and trying to make it happen.”
“I think we’ll make it.”
While some of the reform proposals being considered would be designed to “encourage more clinical trials” while having “very strong guidelines,” the health secretary said the agencies are interested in the full range of options that could include psychedelic therapies and other “rapid interventions.” One of Kennedy’s personal goals would be to validate the utility of substances like psilocybin over SSRIs for depression.
“We’re looking at that as a whole category of interventions that people should be able to look at and have appropriate access to, and we should roll it out as quickly as possible,” he said.
“This is what we’re anticipating, so I can’t tell you exactly what we’re going to do, but very, very strong therapeutic guidelines, so how they’re applied, what kind of follow-up. Because a lot of these things rewire the brain. If you don’t follow-up, it doesn’t work, or you have a failure rate. So we’re developing all of those things and I think we’re developing protocols. People in the administration are eager to do that as soon as possible. I know Doug Collins is doing 21 studies at the VA that they are doing, that they are very promising.
“You need those guidelines because you don’t want to do the Wild West. You can have horror stories overnight because some people can have very, very bad experiences,” Kennedy said. “We’re looking at ways to do it so it’s in a very controlled environment.”
Asked to expand on how Rogan sees the future of psychedelic therapies and whether it will include people in the military or other non-frontline roles, the secretary said he would “personally” like to see broad access, but “we have to take baby steps because you don’t want to create a situation where people want to get hurt.”
However, “you shouldn’t have a soldier who has given everything for the country, who has suffered terribly, who has come to Tijuana to receive these treatments, leave our country to receive treatments,” he said. “It doesn’t make sense.”
“I’ve seen so much overwhelming anecdotal evidence,” Kennedy said, emphasizing that one of his relatives has benefited from psychedelic therapy“but also clinical studies that verify the effect.” And officials at agencies like the NIH and FDA are “doing everything they can to make that happen.”
Last October, Kennedy specifically criticized the FDA under the previous administration for the agency’s “eradication of psychedelics” and a laundry list of other issues that he said was a “war on public health” that would end under the Trump administration.
Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.
Well, it’s not 2026 photos, but with around 600 photos, we definitely did our best. For the past two days, the Netherlands has been the place to be for the global greenhouse industry. From Flower Trials for the horticulture sector, company visits to growers and technical suppliers, as well as dinners, get-togethers, drinks, knowledge sessions and much more. And of course with GreenTech Amsterdam.
The event brought together professionals from around the world to connect, network, share knowledge and do business.
Next week, we’ll be sharing more information on market developments, trends, what’s on display, news, business news, innovations and whatever else you can think of, but for now we’ll stick to photo reporting.
Governor JB Pritzker on Friday gave final approval to the legislation, which cleared the House and Senate about two weeks ago.
As established by law, SB 3222 allows state residents over the age of 21 to possess up to 60 grams of marijuana flower, double the previous law. They can also contain up to 10 grams of concentrated cannabis and infused products with up to 1,000 mg of THC, double the previous limit. Ownership amounts for non-resident adults are also doubled under the bill.
People with past convictions for possession of 60 grams of marijuana will now have the option to have those records expunged; they can double the previous cut, which only those with convictions of up to 30 grams can have the right.
The legislation also recriminalizes hemp THC products with more than 0.4 milligrams of THC per container, in line with the federal ban that will take effect in November.
“Rather than allowing an ambiguous market to put people at risk, Illinois is taking steps to protect consumers of all ages, especially children, from misleading packaging and labeling,” Pritzker said in a press release. “This landmark legislation closes the intoxicating cannabis loophole while strengthening equity and oversight and expanding medical access. Illinois is committed to cultivating a cannabis industry that benefits diverse businesses across the state and prioritizes accessibility, and I’m proud to sign this measure into law.”
Illinois continues to set the standard for opportunity, equity and safety in the adult cannabis industry.
Today, I’m signing legislation to ban the intoxicated sale of marijuana to people under the age of 21 to protect our children, simplify licensing, and strengthen oversight. pic.twitter.com/HEnEdSWe7e
Among other changes, the bill also allows for drive-thru and curbside pickup at dispensaries, allows them to stay open until 2 a.m., and allows medical cannabis certificates to be issued via telehealth.
The hood limits of craft cannabis growers will be expanded to between 5,000 and 14,000 square meters, and the new the law loosens some security requirements for marijuana companies, and also waives or reduces fees for smaller operators.
While broader restrictions on hemp products take effect in the state on Nov. 12, along with a similar federal move, sales to people under the age of 21 are immediately prohibited,
The legislation allows all marijuana dispensaries to register individually to specifically sell medical cannabis. The list of conditions for medical marijuana is also expanding to include female orgasmic disorder, endometriosis, ovarian cysts, and uterine fibroids.
“Illinois has led the nation in building a cannabis industry that prioritizes equity and public safety, and SB 3222 builds on that progress,” Governor Juliana Stratton said. he said. “By protecting young people from intoxicating unregulated hemp products and creating clear standards for the industry, we’re ensuring consumers are safer while maintaining opportunities for diverse businesses and communities across our state.”
Mike Latimer’s photo.
Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.
On May 29, 2026, global cannabis technology company CannBro was invited to the Cannabis Expo in Johannesburg to share insights on emerging cannabis-related medical applications and supply chain strategies in the cannabis markets.
At the event, CannBro highlighted its partnership with the CHEEBA Cannabis Academy to promote industry education, compliance awareness and the development of regulatory standards in emerging cannabis markets. The company highlighted the importance of establishing strong regulatory and compliance frameworks for the sustainable growth of the industry.
As a company certified with ISO 13485 and GMP, CannBro actively explores medical cannabis applications and collaborates with health organizations to discuss potential clinical research and CBD product applications.
CannBro also introduced the “Factory Pricing + Local Stock” strategy, combining manufacturing capabilities in China with warehouses located overseas, enabling efficient delivery of local inventory. The company currently operates warehouses in the United States, Canada, Germany and South Africa and has helped more than 150 customers with local stock delivery solutions that reduce costs and improve inventory turnover.
In addition, CannBro visited local cannabis cultivation facilities to learn about the evolution of the South African market and explore potential partnerships for cultivation, medical applications and product development.
Andy Zhao, CEO of CannBro, said: “As the global cannabis market matures, fulfillment and medical applications will become key drivers of sustainable growth. CannBro remains committed to advancing the industry through education, medical research and supply chain innovation.”